Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic MelanomaRichard P. Tobin, Martin D. McCarter, Dasha T. Cogswell et al.|Clinical Cancer Research|2022Cited by 89
Supplementary table 3 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic MelanomaRichard P. Tobin, Martin D. McCarter, Dasha T. Cogswell et al.|Unknown|2023Cited by 0
Supplementary table 4 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic MelanomaRichard P. Tobin, Martin D. McCarter, Dasha T. Cogswell et al.|Unknown|2023Cited by 0
Supplementary table 2 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic MelanomaRichard P. Tobin, Martin D. McCarter, Dasha T. Cogswell et al.|Unknown|2023Cited by 0
Supplementary Figure S1 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic MelanomaRichard P. Tobin, Martin D. McCarter, Dasha T. Cogswell et al.|Unknown|2023Cited by 0